Companies › Alkermes
3 active drug programs in 8 registered trials: 4 Phase 2, 4 Phase 3; Psychiatry, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALKS 2680 Hypocretin/orexin pathway modulator | HCRT | Phase 3 | Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia | Nov 2026 |
| Samidorphan Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist | OPRM1, OPRK1, OPRD1 | Phase 3 | Schizophrenia | – |
| ALKS 7290 NMDA receptor antagonist | – | Phase 2 | Attention Deficit Disorder With Hyperactivity (ADHD); Major Depressive Disorder (MDD) | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05303064 | Samidorphan | Phase 3 | Schizophrenia | Psychiatry | Sep 2026 |
| NCT06843590 | ALKS 2680 | Phase 2 | Idiopathic Hypersomnia | Neurology | Nov 2026 |
| NCT07455383 | ALKS 2680 | Phase 3 | Narcolepsy Type 1 | Neurology | May 2027 |
| NCT07502443 | ALKS 2680 | Phase 3 | Narcolepsy Type 2 | Neurology | May 2027 |
| NCT07540897 | ALKS 2680 | Phase 3 | Narcolepsy Type 1 | Neurology | Jun 2027 |
| NCT07755410 | ALKS 7290 | Phase 2 | Attention Deficit Disorder With Hyperactivity (ADHD) | Psychiatry | Jul 2027 |
| NCT07901179 | ALKS 7290 | Phase 2 | Major Depressive Disorder (MDD) | Psychiatry | Jan 2028 |
| NCT06767683 | ALKS 2680 | Phase 2 | Narcolepsy Type 1 | Neurology | Jun 2030 |
Cash and short-term investments of $755m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Neurocrine Biosciences Supernus Pharmaceuticals Definium Therapeutics US Intra-Cellular Therapies ACADIA Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.